Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Trulicity ® (dulaglutid) injektion
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Post Hoc Analysis - Baseline Beta-Cell Function
A pooled post hoc analysis of 3 AWARD studies, AWARD-1, -3, and -6, was conducted to evaluate the effect of baseline beta-cell function on the glycemic response from dulaglutide treatment in patients with T2DM. Baseline beta-cell function was estimated by HOMA2-%B. Patients were categorized into 3 subgroups based on low, middle, or high baseline HOMA2-%B tertiles.1
After 26 weeks of treatment with dulaglutide and adjusting for differences in baseline HbA1c levels, the LSM reduction in HbA1c was similar across the 3 tertiles. The high-tertile baseline HOMA2-%B subgroup was noted with a greater numerical LSM reduction in HbA1c compared with the low-tertile baseline HOMA2-%B subgroup (Table 1).1,2
Table 1. Change in HbA1c Levels From Baseline to 26 Weeks Stratified by Tertiles of Baseline HOMA2-%B - Pooled Post Hoc Analysis From AWARD-1, -3, and -6 Studies1,2
|
HbA1c, %a |
DU
1.5 mg |
DU
1.5 mg |
DU
1.5 mg |
DU
0.75 mge |
DU
0.75 mge |
DU
0.75 mge |
|
Change from baseline to 26 weeks |
-1.00 |
-1.03 |
-1.18 |
-0.72 |
-0.94 |
-0.91 |
Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; DU = dulaglutide; HbA1c = glycated hemoglobin; HOMA2-%B = homeostasis model assessment 2 of beta-cell function; LSM = least squares mean.
a Data presented as LSM (95% CI).
b HOMA2-%B of 3.5% to 43.9%.
c HOMA2-%B of 44.2% to 73.9%.
d HOMA2-%B of 74.4% to 258.4%.
e Based on data from AWARD-1 and AWARD-3.
f HOMA2-%B of 4.6% to 43.8%.
g HOMA2-%B of 44.2% to 73.7%.
h HOMA2-%B of 74.4% to 463.5%.
1. Mathieu C, Del Prato S, Botros FT, et al. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes Obes Metab. 2018;20(8):2023-2028. http://dx.doi.org/10.1111/dom.13313
2. Mathieu C, Botros FT, Thieu V, et al. Effect of once-weekly dulaglutide by baseline β-cell function in the AWARD program [abstract]. Diabetes. 2016;65(suppl 1):A269. http://diabetes.diabetesjournals.org/content/65/Supplement_1/A221
Glossary
AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes
HbA1c = glycated hemoglobin
HOMA2-%B = homeostasis model assessment 2 of beta-cell function
LSM = least squares mean
T2DM = type 2 diabetes mellitus
Datum fӧr senaste ӧversyn 2018 M10 31